Nelson Advisors: This Week in European HealthTech, MedTech and Health AI: 23rd October 2026
Here’s a roundup of the past week in European HealthTech. The biggest stories are a surgical-robotics deal, a regulatory-infrastructure raise, and a Nordic consolidation move.
Deals and funding
Stryker–CMR Surgical (Cambridge, UK). The week’s headline. Stryker plans to invest approximately $400 million in CMR Surgical through a strategic alliance that gives it exclusive US sales rights to the Versius robotic surgery system and an option to acquire the company. The ~£300m preferred equity investment comes with an exclusive option for Stryker to buy the remaining equity, while CMR keeps leading development and commercialisation outside the US; Stryker’s Andy Pierce joins CMR’s board.
Scarlet (London) — $50M Series B. Scarlet, a certification body for AI and software medical devices, raised a $50 million Series B led by Headline, with Notion Capital joining and Atomico, Creandum, Kindred and Entrepreneurs First returning. Its pitch is speed: training an AI diagnostic takes weeks while assessment runs 12–18 months; the money goes to US and Asia-Pacific expansion and more AI reviewers. Customers reportedly include Flo Health, DeepHealth and NHS England.
Yazen (Sweden) — €50M. Yazen Health raised €50 million, led by Verdane with Evli Growth Partners, on 13th October — its largest round to date, to scale digital weight-loss care across Europe.
Sleep Cycle / Audiowell (Sweden). Audiowell is going public via a reverse takeover of Sleep Cycle in a SEK 2.25B deal, a notable Nordic consumer-health consolidation.
UK earlier-stage: Stride raised £4.6M seed for its DNA, blood and gut-testing preventative health membership, with Arāya Ventures, Morgan Stanley Inclusive & Sustainable Ventures, Better Ventures, Innovate UK and an a16z Scout investor. Bristol’s Siloton won a €9.98M Innovate UK contract for a handheld eye-imaging system, Unravel Health raised €2.96M for an at-home hormone lab, and Flo reportedly drew undisclosed investment from Google. Silvia Bio (£3m seed, Sheffield) and Medcotec (£2.4m seed, Daresbury) also closed.
Adjacent bio/AI: OMass Therapeutics closed an oversubscribed €275m Series C, and Microbiotica announced a €42m Series C first close led by the British Business Bank.
The macro picture
Tech.eu counted 65+ European deals worth over €1.8B last week, with healthtech second only to fintech at €478M; the UK led by country at €694M. UK startups raised £877.6m in the week of 12th–16th October, led by healthtech, biotech and AI. That said, one commentator notes the breadth is thin: all of the week’s European healthtech activity in their tracker came from the UK, and the largest European cheque was a government contract rather than a VC round.
Nelson Advisors published a sobering piece on sector liquidity this week: by late 2024, invested capital in European Series B healthcare rounds had fallen roughly 84% from 2021 peaks, and the gap between rounds stretched toward 1,000 days.
Policy, regulation and platforms
WHO/Europe released a new tool for building trust in health data on 22 October, ahead of its Regional Committee session on 27th–29th October.
The Commission’s Virtual Human Twins annual event ran 20th–21st October, and an online event looked at moving digital health solutions from pilot to system-wide adoption via TEFs and EDIHs.
The first 2027 Horizon Europe Health calls open on 29th October and close 17th February 2027.
On the vendor side, Epic announced “Connectors” at its October Open@Epic gathering, enabling AI agents to pull data and take actions across third-party systems — relevant for European providers on Epic.
Themes to watch: US strategics buying optionality on European medtech (Stryker/CMR), certification capacity for AI devices becoming its own market (Scarlet), and GLP-1-era digital obesity care drawing growth capital (Yazen).
>>>>
Here’s the Health-AI-specific view for the past week. Governance and public infrastructure dominated; the private-market stories were mostly about regulatory plumbing rather than new models.
Governance and regulation
Poland signs with HealthAI (21st Oct). Poland’s Ministry of Health signed an agreement with HealthAI, the global agency for responsible AI in health, advancing AI governance across Europe; this follows Portugal becoming the first EU member state to join HealthAI’s Global Regulatory Network. HealthAI’s Global Governance Forum is in London on 18th November.
WHO/Europe’s warning on ungoverned AI. Two-thirds of the 53 WHO Europe countries are already deploying AI diagnostics and half have AI patient chatbots, but only about one in twelve has a strategy for governing AI — a picture Hans Kluge called concerning for public trust. WHO/Europe also released a new health-data trust tool on 22nd October, ahead of its Regional Committee on 27th–29th October.
EU AI Act timeline, clarified. Under the Digital Omnibus (Regulation 2026/1744), stand-alone high-risk Annex III systems now apply from 2nd December 2027 (moved from August 2026), and AI embedded in regulated products such as medical devices from 2nd August 2028 (moved from August 2027). No MDR or IVDR obligation or deadline moved. A separate proposal to take medical devices out of Annex I Section A is still at committee stage in the European Parliament, with a plenary vote indicated for December 2026.
UK: NHS AI Commission backed, AI Airlock Phase 3. On 6th October the UK government formally endorsed 44 recommendations from the clinician-led NHS Commission on AI in Healthcare and opened MHRA AI Airlock Phase 3 — the shift being toward continuous lifecycle monitoring rather than static approvals.
Public infrastructure and EU programmes
CHAIN (cardiovascular AI network). The European Cardiovascular Health Data and AI Network launched with €20 million from EU4Health, coordinated by the European Society of Cardiology. It builds an EHDS-aligned federated ecosystem, and validated tools will sit in a European repository with “AI Passports” documenting performance, safety and clinical suitability.
COMPASS-AI and sovereign compute. The Commission launched COMPASS-AI to accelerate clinical AI adoption across member states, and the EU opened an €80 million Chips JU call to put European-designed processors into health-data “AI Factories” — aimed at giving European foundation-model builders localised, GDPR-compliant compute.
Poland’s imaging AI (21 Oct). NVIDIA detailed public-sector projects across Europe including Poland’s eHealth Centre building a DGX BasePOD and MONAI system to review X-rays, CT and MRI scans and flag urgent cases.
NHS Copilot rollout deadline. NHS England’s rollout of Microsoft 365 Copilot to 505,000 staff was due to complete by October 2026, after a 30,000-person trial reported ~43 minutes/day saved on admin.
Capital and companies
AI now 48% of European health VC. Dealroom data shows AI-native companies took 48% of all European health venture funding in 2026, up from 22% in 2025, concentrated in ambient scribes/notes and preventive diagnostics.
Scarlet ($50M Series B, 12 Oct) — the AI and software-only notified body, is the clearest “regulatory capacity as a market” bet (covered in my last message).
Tandem Health deepened EHR integrations across the UK and Nordics after its $100M Series B; Neko Health kept scaling, and SpectaCell launched with funding for computer-vision immunotherapy target validation.
Consolidation thesis for scribes. Nelson Advisors expects H2 2026 to concentrate institutional money in a small tier of multilingual platform players (Nabla, Tandem, etc.) while standalone single-feature scribes get absorbed via M&A.
Adjacent: GE HealthCare’s $945M deal for SOFIE Biosciences, and Epic’s “Connectors” (agentic AI acting across third-party systems) announced at Open@Epic, relevant to European Epic sites.
Read across: The week’s signal is that Europe is building the scaffolding, governance networks, AI passports, sovereign compute, AI-native certification, faster than it’s funding new clinical models. Investors are following that, backing infrastructure and admin AI over diagnostics.
>>>>
Here’s the device side picture this .week. The standout is a UK regulatory decision that landed on Wednesday, plus the Stryker–CMR deal and a cluster of EU rule making.
Regulation and market access
UK makes EU CE mark recognition permanent (21st Oct). The government confirmed on 21st October that it will continue to accept CE-marked medical devices and IVDs in Great Britain on a long-term basis, so the UK will not require a separate approval route for devices already approved for the EU market. More than 90% of devices registered in Britain carry a CE mark. The decision effectively shelves post-Brexit plans that would have forced CE-marked medtech to secure a UKCA tag by 2030. For European manufacturers this removes a looming duplicate-certification cost; for the MHRA it signals a reliance model rather than a divergent one.
MedTech Europe pushes a single pathway for AI devices (15th Oct). The association argued that the MDR/IVDR revision is the critical moment to avoid two parallel product-regulatory systems with overlapping, divergent requirements for AI-enabled devices and diagnostics — i.e. fold AI Act obligations into device law rather than run them side by side. The proposal to move devices out of the AI Act’s Annex I Section A remains at committee stage, with a plenary vote indicated for December 2026.
IVDs risk being left behind in the MDR/IVDR rewrite. A 24th September Euractiv report found only a fraction of MEPs’ amendments address IVD-specific issues, and MedTech Europe is pressing for changes reflecting diagnostics’ distinct performance-study and evidence requirements. Its specific IVDR paper was reposted on 6th October.
EU HTA: first joint clinical assessments for devices. In early October the Commission adopted its first decision selecting two medical devices for joint clinical assessment under the EU HTA regulation — the first live test of the pan-EU evidence bar for devices.
Commission MedTech Accelerator. The Commission launched operational stakeholder frameworks for a four-year translation initiative linking clinical infrastructure to streamline validation for hardware and bio-hybrid technologies, so prototypes don’t stall between bench research and CE-mark readiness.
Deals and product approvals
Stryker–CMR Surgical. Stryker’s ~$400M (£300m) preferred-equity investment, exclusive US distribution for Versius and an option to acquire CMR outright is the week’s biggest European device transaction (details in my first message).
Medtronic Vitalis CE mark (19 Oct). Medtronic received a CE mark for its Vitalis portfolio of five pacemakers with conduction-system-pacing features; ReSyncra CSP is positioned for patients who may benefit from CRT but are failed by traditional approaches. The devices slot into a cardiac-rhythm unit growing mid-teens year over year.
Siloton (Bristol). A €9.98M Innovate UK contract for a handheld eye-imaging system — the largest European device cheque in one tracker’s week, and non-dilutive.
Earlier-stage hardware: Undecimal Bio (Cambridge) launched with a €16M seed, MintNeuro (Imperial spin-out) raised $5M for chips for neural devices, Unravel Health raised €2.96M for an at-home hormone lab, and Medcotec (Daresbury) £2.4m seed.
Adjacent, non-European but relevant to EU pathology/imaging buyers: Agilent agreed to buy digital-pathology firm Proscia for $240M, and Zimmer Biomet extended its Think Surgical robotics distribution deal.
Sector context
MedTech Europe’s Facts & Figures 2026 shows employment above 950,000 and patent filings at record highs, but a narrowing global position. Over 60% of healthcare professionals report device shortages.
Large cap earnings: Siemens Healthineers’ most recent quarter (Q3 FY26) showed a 1.27 equipment book to bill but weakness in Diagnostics, with revenue guidance cut and EPS raised on tariff refunds; its Q4 is due in early November. (I couldn’t confirm Philips’ Q3 2026 release this week, so I’ve left it out.)
Read-across: Three forces converged this week — the UK choosing regulatory alignment over divergence, Brussels wrestling with how to layer AI rules on device law without doubling the burden, and US strategics using option structures (Stryker/CMR, Boston Sci/MiRus earlier in the year) to buy into European innovation without paying full price up front.
Nelson Advisors > European Healthcare Technology Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ Events in 2026
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
HealthInvestor Healthcare Summit > September 2026, London, UK
World Health Summit 2026 > October 2026, Berlin, Germany
HLTH USA 2026 > October 2026, USA
Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Leaders in Health Summit 2026 > November 2026, London, UK
Venture Capital World Summit > December 2026, Toronto, Canada
Meet Nelson Advisors @ Events in 2027
Digital Health Rewired > March 2027 > Birmingham, UK
Barclays Health Elevate > March 2027, London, UK
NHS ConfedExpo > June 2027 > Manchester, UK
HLTH Europe > June 2027, Amsterdam, Netherlands
Comments